VIDEO: Prolonged bevacizumab failed to improve survival in certain gynecologic cancers
Click Here to Manage Email Alerts
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about a study evaluating the optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.
The findings were presented at the ASCO Annual Meeting.
Results from the large, randomized, phase 3 trial indicated that longer treatment with bevacizumab up to 30 months did not improve survival in these patients.
“This quite well answers the question about the use of prolonged bevacizumab in this setting. It is no more effective, but somewhat more toxic,” Rubin said. “I think people will be inclined not to use it as a prolonged management strategy.
Collapse
Pfisterer J, et al. Abstract 5501. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Click Here to Manage Email Alerts